Strategic funding NunaBio has recently secured significant investment rounds and awards, signaling strong investor confidence and potential for expansion. This presents an opportunity to engage during growth phases to offer scale-up services, partnerships, or contract manufacturing capacity aligned with their near-term milestones.

Scaleable DNA production The company specializes in universal, cell-free DNA solutions with disposable, SaaS-controlled hardware enabling rapid transition from research to commercial scale. This creates a sales angle for selling complementary disruptive hardware, software integration, or service packages that optimize speed, space, and safety in manufacturing workflows.

Clinical development readied NunaBio emphasizes seamless path from discovery to clinical development without delays. There is an opportunity to propose CDMO partnerships for clinical trial DNA production, regulatory-ready materials, and GMP-compliant processes to accelerate therapeutic programs.

Tech stack leverage Current tech stack includes cloud and data tools (AWS, MySQL, HubSpot, Statamic) indicating openness to data-driven, integrated workflows. This opens doors for selling data management, analytics, or integration services to optimize production planning, supply chain, and customer relationship management.

Growth through funding With revenue in the low millions and an $12M funding backdrop, NunaBio is positioned for expansion in capabilities and geographic reach. Sales conversations can target scalable contract manufacturing, regional partnerships, and advisory services to support rapid growth and market penetration.